Aquestive Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aquestive Therapeutics, Inc.
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
Keeping Track: US FDA Novel Approvals Return With Xenpozyme, Spevigo Nods; Stimufend Survives COVID-19 Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- MidaSol Therapeutics LP
- MonoSol Rx
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.